New FP7 eHealth Project - preDiCT

The preDiCT project officially launched 1 June 2008, with a mission to model, simulate, and ultimately predict the impact of pharmacological compounds on the heart's rhythm using computer models. This will require advances beyond the current state-of-the-art in:
  • Mathematical models of individual ion channels, which control how and when cells contract;
  • Tissue models, which encapsulate chemical processes and physical relationships at millions of separate points in the heart; and
  • The computer code, which must compute these relationships as a series of complex equations, to enable faster-than-real-time simulation of a beating heart.

Current best practice in pharmaceutical development relies on the Q-T interval (the spacing of two points on an electrocardiogram) as a proxy for potential danger. However, it is known that some drugs which fail this test do not lead to arrhythmia (e.g. Ranolazine, whose safety was demonstrated by the Oxford team). We hope to be able to develop more accurate gauges of potential cariotoxicity.

About 40% of drug candidates fail to come to market due to adverse impact on heart rhythm. preDiCT project hope to achieve better understanding of the underlying mechanisms, which may lead to refinement of the drug development process to avoid these side effects.

By extending the frontiers of "in silico" experimentation, the proposed project will enable future researchers to refine, replace and ultimately reduce the use of animals in pharmaceutical and other cardiac research.

The preDiCT project is embedded in the broader VPH initiative, with direct links to two other FP7-funded VPH projects: The Integrating Project euHeart, which will focus on patient-specific simulation for treatment of cardiovascular disease (17 partners, jointly coordinated by the Philips Technology Research Laboratory and the University of Oxford) and the Virtual Physiological Human Network of Excellence, a service to the community of VPH researchers (13 core partners plus broader membership, jointly coordinated by University College London and the University of Oxford).

The preDiCT project partners are:

  • F. Hoffmann-La Roche AG
  • Szegedi Tudományegyetem
  • Fujitsu Laboratories of Europe Limited
  • Glaxo Smithkline Research and Development
  • Universidad Politécnica de Valencia
  • Centro di Ricerca, Sviluppo e Studi Superiori in Sardegna
  • Novartis Pharma AG
  • Aureus Pharma SA

For further information, please visit:

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...